Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TYMS | P04818 | 1/20 | 0.44 |
| ▸ | CMA1 | P23946 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19925941 | 0.86 | POLB (0.50) | ALOX15KDM4EALDH1A1MAPTCYP1A2 | |
| SCHEMBL19927128 | 0.84 | CYP1A2 (0.46) | ALOX15KDM4EALDH1A1MAPTCYP1A2 | |
| SCHEMBL1197498 | 0.84 | LMNA (0.68) | ALOX15KDM4EALDH1A1MAPTLMNA | |
| SCHEMBL3169680 | 0.82 | POLB (0.61) | KDM4EALDH1A1MAPTLMNASMN1; SMN2 | |
| SCHEMBL18096004 | 0.81 | KDM4E (0.51) | ALOX15KDM4EALDH1A1MAPTCYP1A2 | |
| SCHEMBL1197496 | 0.81 | ALDH1A1 (0.51) | ALOX15KDM4EALDH1A1MAPTCYP1A2 | |
| SCHEMBL2360443 | 0.81 | SLC2A1 (0.58) | ALDH1A1LMNASMN1; SMN2GAARAB9A | |
| SCHEMBL21288734 | 0.81 | KDM4E (0.47) | ALOX15KDM4EALDH1A1MAPTCYP1A2 | |
| SCHEMBL17627070 | 0.80 | KDM4E (0.56) | KDM4EALDH1A1MAPTCYP1A2CYP3A4 | |
| SCHEMBL22412857 | 0.80 | MAPT (0.50) | ALOX15KDM4EALDH1A1MAPTCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250177396-A1 | POLO-LIKE KINASE 4 (PLK4) INHIBITORS, PHARMACEUTICAL COMPOSITIONS, METHODS OF PREPARATION AND USES THEREOF | REPARE THERAPEUTICS INC. (CA) | 2025-06-05 | — | — | US | disclosed |
| EP-4482833-A1 | POLO-LIKE KINASE 4 (PLK4) INHIBITORS, PHARMACEUTICAL COMPOSITIONS, METHODS OF PREPARATION AND USES THEREOF | Repare Therapeutics Inc. (CA) | 2025-01-01 | — | — | EP | disclosed |
| CN-118946560-A | POLO-like kinase 4 (PLK 4) inhibitors, pharmaceutical compositions, methods for their preparation and uses | 修复治疗公司 | 2024-11-12 | — | — | CN | disclosed |
| US-20240368189-A1 | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator, Pharmaceutical Compositions, Methods of Treatment, and Process for Making the Modulators | VERTEX PHARMA (US) | 2024-11-07 | — | — | US | disclosed |
| WO-2023159307-A9 | POLO-LIKE KINASE 4 (PLK4) INHIBITORS, PHARMACEUTICAL COMPOSITIONS, METHODS OF PREPARATION AND USES THEREOF | REPARE THERAPEUTICS INC. (CA) | 2024-03-21 | — | — | WO | disclosed |
| US-11866450-B2 | Modulators of Cystic Fibrosis Transmembrane Conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-01-09 | — | — | US | disclosed |
| WO-2023159307-A1 | POLO-LIKE KINASE 4 (PLK4) INHIBITORS, PHARMACEUTICAL COMPOSITIONS, METHODS OF PREPARATION AND USES THEREOF | REPARE THERAPEUTICS INC. (CA) | 2023-08-31 | — | — | WO | disclosed |
| EP-4198037-A1 | MACROCYCLES AS MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR USE IN THE TREATMENT OF CYCSTIC FIBROSIS | Vertex Pharmaceuticals Incorporated (US) | 2023-06-21 | — | — | EP | disclosed |
| EP-4198037-A1 | MACROCYCLES AS MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR USE IN THE TREATMENT OF CYCSTIC FIBROSIS | Vertex Pharmaceuticals Incorporated (US) | 2023-06-21 | — | — | EP | disclosed |
| EP-3752510-B1 | MACROCYCLES AS MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS THEREOF, THEIR USE IN THE TREATMENT OF CYCSTIC FIBROSIS, AND PROCESS FOR MAKING THEM | VERTEX PHARMA (US) | 2022-12-07 | — | — | EP | disclosed |
| WO-2019161078-A1 | MACROCYCLES AS MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS THEREOF, THEIR USE IN THE TREATMENT OF CYCSTIC FIBROSIS, AND PROCESS FOR MAKING THEM | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-08-22 | — | — | WO | disclosed |
| WO-2019161078-A1 | MACROCYCLES AS MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS THEREOF, THEIR USE IN THE TREATMENT OF CYCSTIC FIBROSIS, AND PROCESS FOR MAKING THEM | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-08-22 | — | — | WO | disclosed |
| US-20190248809-A1 | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator, Pharmaceutical Compositions, Methods of Treatment, and Process for Making the Modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-08-15 | — | — | US | disclosed |
| US-20190248809-A1 | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator, Pharmaceutical Compositions, Methods of Treatment, and Process for Making the Modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-08-15 | — | — | US | disclosed |
| EP-2379557-B1 | AMINO PYRAZOLE COMPOUND | LILLY CO ELI (US) | 2012-10-31 | — | — | EP | disclosed |
| EP-2379557-A1 | AMINO PYRAZOLE COMPOUND | Eli Lilly and Company (US) | 2011-10-26 | — | — | EP | disclosed |
| US-7897600-B2 | Amino pyrazole compound | ELI LILLY AND COMPANY (US) | 2011-03-01 | — | — | US | disclosed |
| US-20100286139-A1 | AMINO PYRAZOLE COMPOUND | ELI LILLY AND COMPANY (US) | 2010-11-11 | — | — | US | disclosed |
| WO-2010074947-A1 | AMINO PYRAZOLE COMPOUND | ELI LILLY AND COMPANY (US) | 2010-07-01 | — | — | WO | disclosed |
| US-20100152181-A1 | AMINO PYRAZOLE COMPOUND | ELI LILLY AND COMPANY (US) | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286139-A1 | AMINO PYRAZOLE COMPOUND | MCL1, MYC, PML | ALOX15 4005/4885KDM4E 580/4885ALDH1A1 2620/4885 |
| US-20250177396-A1 | POLO-LIKE KINASE 4 (PLK4) INHIBITORS, PHARMACEUTICAL COMPOSITIONS, METHODS OF PREPARATION AND USES THEREOF | PLK4, PLK2, PLK3 | ALOX15 3707/4885KDM4E 752/4885ALDH1A1 2707/4885 |
| US-20240368189-A1 | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator, Pharmaceutical Compositions, Methods of Treatment, and Process for Making the Modulators | CFTR, SLC26A4, ABCB11 | ALOX15 2089/4885KDM4E 4114/4885ALDH1A1 1912/4885 |
| US-11866450-B2 | Modulators of Cystic Fibrosis Transmembrane Conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulators | CFTR, SLC26A4, ABCB11 | ALOX15 2089/4885KDM4E 4114/4885ALDH1A1 1912/4885 |
| US-20190248809-A1 | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator, Pharmaceutical Compositions, Methods of Treatment, and Process for Making the Modulators | CFTR, SLC26A4, ABCB11 | ALOX15 2089/4885KDM4E 4114/4885ALDH1A1 1912/4885 |
| US-20100152181-A1 | AMINO PYRAZOLE COMPOUND | MCL1, MYC, PML | ALOX15 4005/4885KDM4E 580/4885ALDH1A1 2620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.